Eliem Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	93.11	43.59	46.92	20.49	21.22
Short-Term Investments	13.69	79.98	89.56	0	0
Cash & Cash Equivalents	106.8	123.57	136.48	20.49	21.22
Cash Growth	-13.57%	-9.46%	566.18%	-3.47%	-
Other Current Assets	3.46	10.83	11.77	1.51	0.06
Total Current Assets	110.26	134.39	148.25	22	21.28
Property, Plant & Equipment	0.2	0.47	0	0	0
Long-Term Investments	0	0	24.92	0	0
Other Long-Term Assets	0.02	0.13	0.07	2.63	0.11
Total Long-Term Assets	0.21	0.6	24.99	2.63	0.11
Total Assets	110.47	134.99	173.24	24.63	21.4
Accounts Payable	0.07	0.75	1.4	1.29	0.71
Current Debt	0.33	0.3	0	0	0
Other Current Liabilities	2.43	5.05	4.63	1.77	0.07
Total Current Liabilities	2.83	6.1	6.03	3.06	0.78
Long-Term Debt	0.02	0.18	0	0	0
Other Long-Term Liabilities	0.02	0	0.01	0	0
Total Long-Term Liabilities	0.04	0.18	0.01	0	0
Total Liabilities	2.87	6.28	6.04	3.06	0.78
Total Debt	0.35	0.48	0	0	0
Debt Growth	-27.29%	-	-	-	-
Retained Earnings	-155.98	-120.86	-75.62	-28.14	-7.47
Comprehensive Income	-0	-0.36	-0.12	0	0
Shareholders' Equity	107.6	128.72	167.2	-24.98	-5.56
Net Cash / Debt	106.45	123.09	136.48	20.49	21.22
Net Cash / Debt Growth	-13.52%	-9.81%	566.18%	-3.47%	-
Net Cash Per Share	3.94	4.68	11.13	9.36	12.78
Working Capital	107.42	128.3	142.22	18.94	20.5
Book Value Per Share	3.99	4.89	13.64	-11.42	-3.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).